Treatment of hyperphosphatemia using crosslinked small molecule amine polymers

US7589238B2 · kind B2 · utility

Assignee

• Ilypsa, Inc. · US

Inventors

• Eric Connor · Los Gatos, US
• Dominique Charmot · Campbell, US
• Han-Ting Chang · Livermore, US
• Florence Roger · Santa Clara, US
• Gerrit Klaemer · San Jose, US
• Son H. NGUYEN · Milpitas, US
• Jonathan Mills · San Jose, US
• Jerry M. Buysse · Los Altos, US
• Angela Lee · San Jose, US
• Deidre Madsen · Sunnyvale, US
• Jun Shao · Fremont, US
• Michael J. Cope · Berkeley, US
• John Fordtran · Dallas, US

Key dates

• Filing date: Aug 17, 2006
• Grant date: Sep 15, 2009
• Expiry date: Nov 20, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C08L79/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.